Claims for Patent: 11,174,247

Summary for Patent: 11,174,247

Title:	Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
Abstract:	The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan.
Inventor(s):	Marc BELLET, Martin Bolli, Martine Clozel, Marc IGLARZ
Assignee:	Actelion Pharmaceuticals Ltd , Idorsia Pharmaceuticals Ltd
Application Number:	US16/489,227
Patent Claims:	1. A pharmaceutical composition containing, as active principles, aprocitentan, or a pharmaceutically acceptable salt thereof, in combination with: an angiotensin receptor blocker, or a pharmaceutically acceptable salt thereof; as well as at least one pharmaceutically acceptable excipient. 2. The pharmaceutical composition according to claim 1 wherein said angiotensin receptor blocker is valsartan, or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition according to claim 1, said composition comprising aprocitentan in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 20.0°, and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 4. A pharmaceutical composition according to claim 1, said composition comprising aprocitentan in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 5. The pharmaceutical composition according to claim 1, said composition comprising aprocitentan in crystalline Form A which essentially shows the X-ray powder diffraction pattern as depicted in FIG. 1, wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 6. The pharmaceutical composition according to claim 1, further comprising: a calcium channel blocker, or a pharmaceutically acceptable salt thereof; and a diuretic which is a thiazide-like diuretic, or a pharmaceutically acceptable salt thereof. 7. The pharmaceutical composition according to claim 6, wherein the diuretic is hydrochlorothiazide or a pharmaceutically acceptable salt thereof, or chlorthalidone or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition according to claim 6, wherein angiotensin receptor blocker is valsartan, or a pharmaceutically acceptable salt thereof; the calcium channel blocker is amlodipine, or a pharmaceutically acceptable salt thereof; and the diuretic is hydrochlorothiazide or a pharmaceutically acceptable salt thereof, or chlorthalidone or a pharmaceutically acceptable salt thereof. 9. The pharmaceutical composition according to claim 8, wherein the diuretic is hydrochlorothiazide, or a pharmaceutically acceptable salt thereof. 10. A pharmaceutical composition according to claim 8 wherein: aprocitentan is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 2.5 to 100 mg per day of aprocitentan; valsartan or a pharmaceutically acceptable salt thereof is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 100 to 320 mg per day of valsartan; amlodipine or a pharmaceutically acceptable salt thereof is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 2 to 10 mg per day of amlodipine; and hydrochlorothiazide or a pharmaceutically acceptable salt thereof, if present, is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 5 to 25 mg per day of hydrochlorothiazide; and chlorthalidone or a pharmaceutically acceptable salt thereof, if present, is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 10 to 150 mg per day of chlorthalidone. 11. A pharmaceutical composition according to claim 9 wherein: aprocitentan is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 2.5 to 100 mg per day of aprocitentan; valsartan or a pharmaceutically acceptable salt thereof is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 100 to 320 mg per day of valsartan; amlodipine or a pharmaceutically acceptable salt thereof is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 2 to 10 mg per day of amlodipine; and hydrochlorothiazide or a pharmaceutically acceptable salt thereof is comprised in a pharmaceutical unit dosage form suitable for the oral administration of 5 to 25 mg per day of hydrochlorothiazide. 12. A method for the treatment of hypertension; heart failure; diastolic dysfunction; chronic kidney disease (CKD); or for the reduction of the risk of developing a major cardiovascular event in patients who have diabetes that is accompanied by at least one other cardiovascular risk factor comprising hypertension; comprising the administration of a pharmaceutically effective amount of aprocitentan, or of a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein aprocitentan is administered in combination with a pharmaceutically effective amount of an angiotensin receptor blocker or a pharmaceutically acceptable salt thereof. 13. The method according to claim 12, wherein said angiotensin receptor blocker is valsartan, or a pharmaceutically acceptable salt thereof. 14. The method according to claim 12, wherein aprocitentan is further administered in combination with: a calcium channel blocker, or a pharmaceutically acceptable salt thereof; and a diuretic which is a thiazide-like diuretic, or a pharmaceutically acceptable salt thereof. 15. The method according to claim 14, wherein the angiotensin receptor blocker is valsartan, or a pharmaceutically acceptable salt thereof; the calcium channel blocker is amlodipine, or a pharmaceutically acceptable salt thereof; and the diuretic is hydrochlorothiazide or a pharmaceutically acceptable salt thereof, or chlorthalidone or a pharmaceutically acceptable salt thereof. 16. The method according to claim 15 wherein: aprocitentan or a pharmaceutically acceptable salt thereof is administered in a pharmaceutical unit dosage form suitable for the oral administration of 2.5 to 100 mg per day of aprocitentan; valsartan or a pharmaceutically acceptable salt thereof is administered in a pharmaceutical unit dosage form suitable for the oral administration of 100 to 320 mg per day of valsartan; amlodipine or a pharmaceutically acceptable salt thereof is administered in a pharmaceutical unit dosage form suitable for the oral administration of 2 to 10 mg per day of amlodipine; and hydrochlorothiazide or a pharmaceutically acceptable salt thereof, if present, is administered in a pharmaceutical unit dosage form suitable for the oral administration of 5 to 25 mg per day of hydrochlorothiazide; and chlorthalidone or a pharmaceutically acceptable salt thereof, if present, is administered in a pharmaceutical unit dosage form suitable for the oral administration of 10 to 150 mg per day of chlorthalidone. 17. The method according to claim 12, wherein said method is for the treatment of hypertension. 18. The method according to claim 14, wherein said method is for the treatment of hypertension. 19. A method for the treatment of hypertension, heart failure, or chronic kidney disease (CKD); comprising administering a pharmaceutically effective amount of aprocitentan, or of a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein aprocitentan is administered in combination with a pharmaceutically effective amount of an angiotensin receptor blocker or of a pharmaceutically acceptable salt thereof. 20. The method according to claim 19, wherein said angiotensin receptor blocker is valsartan, or a pharmaceutically acceptable salt thereof. 21. The method according to claim 18, wherein said diuretic is hydrochlorothiazide or a pharmaceutically acceptable salt thereof, or chlorthalidone or a pharmaceutically acceptable salt thereof. 22. The method according to claim 18, wherein said diuretic is hydrochlorothiazide or a pharmaceutically acceptable salt thereof. 23. The method according to claim 18, wherein said diuretic is chlorthalidone or a pharmaceutically acceptable salt thereof. 24. The method according to claim 15, wherein said method is for the treatment of resistant hypertension. 25. The method according to claim 24, wherein said diuretic is hydrochlorothiazide or a pharmaceutically acceptable salt thereof. 26. The method according to claim 16, wherein said method is for the treatment of resistant hypertension. 27. The method according to claim 12, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 28. The method according to claim 13, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 29. The method according to claim 14, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 30. The method according to claim 15, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 31. The method according to claim 16, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 32. The method according to claim 18, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 33. The method according to claim 24, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 34. The method according to claim 26, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 35. The method according to claim 16, wherein aprocitentan is administered in a pharmaceutical unit dosage form suitable for the oral administration of 10 to 50 mg per day of aprocitentan. 36. The method according to claim 26, wherein aprocitentan is administered in a pharmaceutical unit dosage form suitable for the oral administration of 10 to 50 mg per day of aprocitentan. 37. The method according to claim 19, wherein said method is for the treatment of chronic kidney disease (CKD). 38. The method according to claim 37, wherein said method is for the treatment of CKD of stages 1 to 4 caused by or associated with essential hypertension. 39. The method according to claim 20, wherein said method is for the treatment of chronic kidney disease (CKD). 40. The method according to claim 39, wherein said method is for the treatment of CKD of stages 1 to 4 caused by or associated with essential hypertension. 41. The method according to claim 37, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 42. The method according to claim 39, wherein the aprocitentan is in crystalline Form A characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ+/−0.2°. 43. The method according to claim 17, wherein said hypertension is resistant hypertension. 44. The method according to claim 18, wherein said hypertension is resistant hypertension. 45. The method according to claim 12, wherein the method to be treated is chronic heart failure. 46. The method according to claim 17, wherein aprocitentan is administered in a pharmaceutical unit dosage form suitable for the oral administration of 10 to 50 mg per day of aprocitentan. 47. The method according to claim 23, wherein aprocitentan is administered in a pharmaceutical unit dosage form suitable for the oral administration of 10 to 50 mg per day of aprocitentan.